Table 1.
Clinical characteristics of patient groups.
| Characteristic | Study group (n = 14) | Validation group (n = 85) | p-value |
|---|---|---|---|
| Gender (female/male) | 2/12 (14.3%/85.7%) | 11/74 (12.9%/87.1%) | >0.999 |
| Age (years) | 52.5 [45.0‒62.8] | 59.0 [50.0‒65.0] | 0.226 |
| BMI (kg/m2) | 25.6 [25.2‒27.5] | 28.7 [26.2‒31.7] | 0.026 |
| Smoking | 6 (42.9%) | 51 (60.7%) | 0.336 |
| Diabetes | 2 (14.3%) | 14 (16.7%) | >0.999 |
| Hypertension | 3 (21.4%) | 55 (64.7%) | 0.006 |
| Hypercholesterolemia | 7 (50%) | 40 (47.6%) | >0.999 |
| Previous MI | 0 (0.0%) | 3 (3.6%) | >0.999 |
| Anterior MI | 7 (53.8%) | 23 (27.1%) | 0.102 |
| NT-proBNP (pg/ml) admission | 1006.3 [431.0‒1820.2] | 860.0 [412.8‒1545.8] | 0.587 |
| NT-proBNP (pg/ml) follow-up | 193.8 [69.5‒786.0] | 174.5 [68.0‒318.5] | 0.427 |
| LVEF (%) admission | 47.0 [42.2‒56.5] | 50.0 [44.2‒55.0] | 0.715 |
| LVEF (%) follow-up | 57.0 [42.0‒66.0] | 56.0 [49.0‒60.0] | 0.633 |
| Medication | |||
| Aspirin | 14 (100%) | 84 (100.0%)* | NA |
| Clopidogrel | 13 (92.9%) | 74 (88.1%) | >0.999 |
| Beta blockers | 14 (100%) | 76 (90.5%) | 0.597 |
| ACE inhibitors | 14 (100%) | 68 (81.0%) | 0.117 |
| Statins | 14 (100%) | 82 (97.6%) | >0.999 |
| Diuretics | 6 (42.9%) | 23 (27.4%) | 0.342 |
Data are presented as number (%) or median [first quartile - third quartile]. P < 0.05 was considered to indicate a statistically significant difference. *Data were only available for n = 84 patients; these numbers were used to calculate percentages. BMI – Body Mass Index; LVEF – Left Ventricular Ejection Fraction; MI – myocardial infarction; NT-proBNP – N-terminal pro-B-type natriuretic peptide.